Technical Analysis for BPMC - Blueprint Medicines Corporation

Grade Last Price % Change Price Change
grade D 77.64 2.93% 2.21
BPMC closed up 2.93 percent on Tuesday, April 23, 2019, on 76 percent of normal volume.

Earnings due: May 2

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical BPMC trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup 2.93%
Lower Bollinger Band Walk Weakness 2.93%
Lower Bollinger Band Touch Weakness 2.93%
Oversold Stochastic Weakness 2.93%
Doji - Bullish? Reversal 5.13%
Lower Bollinger Band Walk Weakness 5.13%

Older signals for BPMC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.
Biopharmaceutical Cancer Cell Biology Cell Signaling Tyrosine Kinase Receptors Protein Kinase Inhibitor Mastocytosis Tyrosine Kinase Gastrointestinal Stromal Tumor Myeloproliferative Neoplasm Rare Genetic Disease Rare Genetic Diseases Systemic Mastocytosis
Is BPMC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 89.0
52 Week Low 44.58
Average Volume 493,529
200-Day Moving Average 68.9958
50-Day Moving Average 79.8964
20-Day Moving Average 79.8565
10-Day Moving Average 78.285
Average True Range 3.5175
ADX 22.54
+DI 16.2116
-DI 25.6471
Chandelier Exit (Long, 3 ATRs ) 75.6675
Chandelier Exit (Short, 3 ATRs ) 82.4725
Upper Bollinger Band 86.2699
Lower Bollinger Band 73.4431
Percent B (%b) 0.33
BandWidth 16.062312
MACD Line -1.1123
MACD Signal Line -0.3092
MACD Histogram -0.8031
Fundamentals Value
Market Cap 3.04 Billion
Num Shares 39.1 Million
EPS -3.12
Price-to-Earnings (P/E) Ratio -24.88
Price-to-Sales 103.31
Price-to-Book 7.06
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 82.64
Resistance 3 (R3) 82.33 80.37 81.80
Resistance 2 (R2) 80.37 79.09 80.52 81.52
Resistance 1 (R1) 79.00 78.31 79.69 79.31 81.25
Pivot Point 77.04 77.04 77.38 77.19 77.04
Support 1 (S1) 75.67 75.76 76.36 75.98 74.03
Support 2 (S2) 73.71 74.98 73.86 73.76
Support 3 (S3) 72.34 73.71 73.48
Support 4 (S4) 72.65